송윤경 조교수
Song Yun-Kyoung
- 02-2164-5515
- yksong@catholic.ac.kr
- 정진석추기경약학관 NP410
연구분야
약료서비스 모델 개발, 의약품 안전성유효성 평가, 맞춤형 건강증진 연구
연구키워드
약료서비스
안전성
건강증진
실사용데이터
교수소개
약료서비스 모델 개발을 위한 임상연구, RWD를 이용한 의약품 안전성, 유효성 분석 연구 및 맞춤형 건강증진 방안을 주로 연구하고 있다. 2017년 서울대학교 약학대학에서 임상약학 전공으로 박사학위를 받았으며 2018-2023년 동안 대구가톨릭대학교 약학대학에서 조교수로 재직 후 2023년부터 현재까지 가톨릭대학교 약학대학에서 임상약료학 연구실을 운영해 오고 있다. 2005-2014년 동안 식품의약품안전처에서 보건연구사로 재직하며 의약품 안전성/유효성 자료 심사 업무를 수행하였다. 미국 등과 활발한 국제공동연구를 수행하고 있으며 현재까지 총 50여편의 논문을 SCI급 국제학술지에 발표했다. 또한 다수의 한국연구재단 및 식품의약품안전처 지원의 연구과제를 수행중에 있다. 임상약학 분야의 핵심 학술단체인 한국임상약학회의 총무위원장, 식품의약품안전처 중앙약사심의위원회 위원, 한국의약품안전관리원 DUR 분과위원 및 의약품부작용 전문위원회 전문가단으로도 활동 중이다.
Major research areas are clinical studies for the development of pharmaceutical care service models, analysis of drug safety and efficacy using real-world data, and personalized health promotion researches. She obtained a doctoral degree in Clinical Pharmacy from the College of Pharmacy, Seoul National University in 2017 and worked as an assistant professor at the College of Pharmacy, Daegu Catholic University from 2018 to 2023. Since 2024, She has been a professor in a clinical pharmacy lab at the College of Pharmacy, the Catholic University of Korea. She worked as a reviewer at the Ministry of Food and Drug Safety (MFDS) during 2005-2014. She has collaborated with researchers in the United States and Australia, and has published over 50 papers in SCI journals. Additionally, She is currently involved in several research projects supported by the National Research Foundation and the MFDS. She has been the secretary-general of the Korean College of Clinical Pharmacy and a member of the Central Pharmaceutical Review Committee of the MFDS. She has also been a member of the DUR subcommittee and an expert member of the Adverse Drug Reaction Expert Committee of the Korea Institute of Drug Safety and Risk Management.
최종학력
2017.02.24 | 서울대학교 | 약학과 | 박사
연구실적
-
2024.04
| 제1저자
| RMD OPEN, 제10권 2호
Comparison of active tuberculosis occurrence associated with Janus kinase inhibitors and biological DMARDs in rheumatoid arthritis
- JH Kim, et al., Utilizing Temporal Pattern of Adverse Event Reports to Identify Potential Late-onset Adverse Events. Expert Opin Drug Saf. 2024 (Corresponding) - S-H Cha, et al. Comparison of Cutaneous Adverse Events Between Second-Generation Tyrosine Kinase Inhibitors and Imatinib for Chronic Myeloid Leukemia: A Systematic Review and Meta-analysis. Acta Oncologica, 2023 (Corresponding) - JH Kim, et al., Performance of Cardiovascular Risk Prediction Models in East Asian Patients with New-onset Rheumatoid Arthritis: National Cohort Study. J Am Heart Assoc. 2023 (Corresponding) - Y-K Song, et al., Comparison of Cardiovascular Risk of Janus Kinase Inhibitors and Biologic Disease-Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis Without Underlying Cardiovascular Diseases: A Nationwide Cohort Study. Front Pharmacol. 2023 (First author) - Y-K Song, et al., Objective structured clinical examination as a competency assessment tool of students' readiness for advanced pharmacy practice experiences in South Korea: a pilot study. BMC Med Edu. 2023 (First author) - SJ Song, Y-K Song, et al., Prognostic Significance of Severity of Immune-Related Adverse Events in Advanced Cancer Patients Treated with PD-1/PD-L1 Inhibitors: A Real-World Data Analysis. Target Oncol. 2023 (First author)
- Y-KS et al., Potential Adverse Events Reported with the Janus Kinase Inhibitors Approved for the Treatment of Rheumatoid Arthritis using Spontaneous Reports and Online Patient Reviews. Front Pharmacol. 2022 (First author) - J-EP et al., Impact of Pharmaceutical care service for patients with RheumatOid arthritis Using customised mobile Device (the PROUD trial): study protocol for a randomised controlled trial. BMJ Open, 2022 (Corresponding) - Y-KS et al., Employee perspectives on onsite health clinics in semiconductor company In South Korea. IJERPH. 2022 (First author) - S-H Cha et al., Analysis of Important Medical Adverse Events and Signals Related with Cyclosporine and Tacrolimus Using the FAERS. Korean J Clin Pharm, 2022 (Corresponding) - Y-KS et al., Effectiveness of Clinical Pharmacist Service on Drug-Related Problems and Patient Outcomes for Hospitalized Patients with Chronic Kidney Disease: A Randomized Controlled Trial. J Clin Med. 2021 (First author) - Y-KS et al., Nationwide prevalence of potential drug-drug interactions associated with non-anticancer agents in patients on oral anticancer agents in South Korea, Support Care Cancer, 2020 (First author) - Y-KS et al., International Coherence of Pediatric Drug Labeling for Drug Safety: Comparison of Korean MFDS and US FDA Approved Labels. Clinical Pharmacology & Therapeutics. 2020 (First author, Featured article)